Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human brucellosis.

María Pía Franco1, Maximilian Mulder, Robert H Gilman

  • 1Department of Neurology, University of Minnesota, Minneapolis, MN, USA.

The Lancet. Infectious Diseases
|November 30, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Continuous EEG Monitoring and Clinical Outcomes in Patients Undergoing ECMO.

Clinical EEG and neuroscience·2025
Same author

Prognostic factors and outcomes in COVID-19 patients requiring prolonged mechanical ventilation: a retrospective cohort study.

Therapeutic advances in respiratory disease·2022
Same author

Association of hypoxic ischemic brain injury on early CT after out of hospital cardiac arrest with neurologic outcome.

The American journal of emergency medicine·2022
Same author

Review of brucellosis in Nepal.

International journal of veterinary science and medicine·2020
Same author

Dual antiplatelet therapy does not improve outcomes after aneurysmal subarachnoid hemorrhage compared with aspirin monotherapy.

Clinical neurology and neurosurgery·2020
Same author

Postcardiac arrest neurological prognostication with quantitative regional cerebral densitometry.

Resuscitation·2020
Same journal

Cefiderocol heteroresistance in NDM Enterobacterales.

The Lancet. Infectious diseases·2026
Same journal

Correction to Lancet Infect Dis 2020; 20: 37-59.

The Lancet. Infectious diseases·2026
Same journal

Correction to Lancet Infect Dis 2020; 20: 60-79.

The Lancet. Infectious diseases·2026
Same journal

Expert consensus on case definitions in human loiasis: a Delphi study.

The Lancet. Infectious diseases·2026
Same journal

The Bundibugyo virus disease outbreak: a warning signal for risks to health workers.

The Lancet. Infectious diseases·2026
Same journal

Trials of medical countermeasures to begin in DR Congo.

The Lancet. Infectious diseases·2026
See all related articles

Human brucellosis remains a challenge, but molecular studies offer insights into pathogenesis. New diagnostics and treatments are emerging, particularly for developing nations, though further research is needed.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Public Health

Background:

  • Human brucellosis, caused by Brucella species, presents ongoing clinical and scientific challenges.
  • Understanding pathogenesis, identifying disease markers, and improving treatment are critical unmet needs.

Purpose of the Study:

  • To review current knowledge on Brucella pathogenesis.
  • To highlight advances in diagnostics and therapeutic options for human brucellosis.
  • To discuss the impact and management of brucellosis in developing countries.

Main Methods:

  • Literature review of molecular studies on Brucella pathogenesis.
  • Analysis of recent technological advancements in diagnostic tools.
  • Synthesis of current therapeutic strategies and control program data.

Related Experiment Videos

Main Results:

  • Molecular research has illuminated Brucella pathogenesis.
  • New diagnostic technologies offer improved detection capabilities, especially for resource-limited settings.
  • Current treatment regimens require further optimization, and control programs need enhancement.

Conclusions:

  • Continued research into pathogenesis and treatment is essential for effective brucellosis management.
  • Accessible diagnostics are crucial for controlling this neglected disease in developing countries.
  • Integrated control programs are necessary for global brucellosis reduction.